Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Antoine GavoilleEmmanuelle LerayRomain MarignierFabien RollotRomain CaseyGuillaume MatheyLaure MichelJérôme de SèzeJonathan CironAurélie RuetÉlisabeth MaillartPierre M. LabaugeHélène ZéphirDavid-Axel LaplaudCaroline PapeixGilles-Louis DeferThibault MoreauEric BergerAnne-Laure DubessyPierre ClavelouEric ThouvenotOlivier HeinzlefJean PelletierAbdullatif Al KhedrOlivier CasezBertrand BourreAbir WahabLaurent MagyJean-Philippe CamdessanchéInès DoghriSolène MoulinCéline LabeyrieKarolina HankiewiczAmélie dos SantosCorinne PottierÉric ManchonMaya TchikviladzeChristine Lebrun-FrenaySandra VukusicLucie Bellon-TabartDelphine CortialFrançois CottonF. GuilleminJavier OlaizBruno StankoffEmmanuelle Le PageNicolas CollonguesArnaud KwiatkowskiSandrine WiertlewskiClaire GiannesiniBertrand AudoinPhilippe CabrePierre DurozardBertrand LapergueChantal NifleJérôme Grimaud
• Organismes : Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Hospices Civils de Lyon École des Hautes Études en Santé Publique Recherche sur les services et le management en santé Arènes: politique, santé publique, environnement, médias Département Méthodes quantitatives en santé publique Université de Rennes Hospices Civils de Lyon Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Observatoire Français de la Sclérose En Plaques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Observatoire Français de la Sclérose En Plaques [Lyon] Fondation Eugène Devic EDMUS Service de neurologie [CHRU Nancy] INterdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes Centre d'investigation clinique - Epidémiologie clinique [Nancy] Service de Neurologie [Rennes] = Neurology [Rennes] Centre d'Investigation Clinique [Rennes] CIC Strasbourg Service de Neurologie [Strasbourg] Centre Ressources et Compétences sclérose en plaques (CRC-SEP) [CHU Toulouse] Institut Toulousain des Maladies Infectieuses et Inflammatoires Service de neurologie [Bordeaux] Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale AP-HP - Hôpital de la Pitié Salpêtrière CHU Montpellier = Montpellier University Hospital Université de Montpellier Lille Neurosciences & Cognition - U 1172 Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology CIC Plurithématique de Nantes Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Université de Caen Normandie Service de Neurologie [CHU Caen] Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Service de Neurologie [CHRU Besançon] AP-HP - Hôpital de la Pitié Salpêtrière Neuro-Dol Service Neurologie [CHU Clermont-Ferrand] Service de Neurologie [CHU Nimes] Institut de Génomique Fonctionnelle Centre Hospitalier Intercommunal de Poissy/Saint-Germain-en-Laye Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Service de neurologie [Amiens] Pôle Psychiatrie et Neurologie [Grenoble] Translational Research in Autoimmunity and Inflammation Group Service de neurologie [Rouen] AP-HP - Hôpital Henri-Mondor Service de Neurologie [CHU Limoges] Service de Neurologie [CHU de Saint-Étienne] Centre Hospitalier Régional Universitaire de Tours Service de neurologie [Reims] AP-HP - Hôpital Bicêtre [Le Kremlin-Bicêtre] Centre Hospitalier de Saint-Denis [Ile-de-France] Service de neurologie [CHU de Poitiers] Centre Hospitalier René Dubos [Pontoise] Centre Hospitalier de Gonesse Hôpital Foch [Suresnes] Hôpital Pasteur [Nice] UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Hospices Civils de Lyon Université Claude Bernard Lyon 1 Observatoire Français de la Sclérose En Plaques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS
• Publié dans Neurology le 01/11/2020

---

Résumé : Background and objectives: In women with multiple sclerosis (MS), the therapeutic strategy may be influenced by the anticipation of future pregnancies, leading to underexposure to disease-modifying therapies (DMTs) and highly effective DMTs (HEDMTs) compared with men. We aimed to evaluate potential therapeutic inertia in women with MS and explore its causes. Methods: We performed a retrospective cohort study based on data extracted on June 2023 from the Observatoire Français de la Sclérose en Plaques for all patients with a relapsing-remitting MS onset between 18 and 40 years. The primary outcome was the annual probability of receiving a DMT, accounting for sex, disease severity, and pregnancy/postpartum periods. Secondary outcomes were the annual probability of receiving a HEDMT, each DMT separately, and interaction of the effect of sex with calendar year, patient age, and disease duration. We used a longitudinal logistic model with generalized estimating equations and an inverse-probability-of-censoring weighting. Results: We included 22,657 patients with MS; 16,857 (74.4%) were female, mean (SD) age at onset was 29.0 (6.0) years, and median (interquartile range) follow-up duration was 11.6 (6.6-17.3) years. Women were significantly less likely to receive a DMT (odds ratio [OR] 0.92, 95% CI 0.87-0.97) or a HEDMT (OR 0.80, 95% CI 0.74-0.86). This difference appeared 2 years after disease onset for DMTs and 1 year for HEDMTs, and did not differ significantly according to patient's age. Teriflunomide, sphingosine-1-phosphate receptor modulators, and anti-CD20s were significantly underused in women throughout their entire period of availability; interferons β (IFN-β) and natalizumab were initially less used and then equally after some time; glatiramer acetate and fumarates were first used equally, then more frequently in women. The proportion of treated women, analyzed from the first childbirth of 5,268 women, began to decline 18 months before childbirth, from 42.6% to 27.9% at the estimated time of conception. Discussion: Women with MS were significantly less exposed to DMTs compared with men. Anticipation of pregnancy was probably an important factor underlying this difference, but also sex-specific therapeutic inertia. Neurologists and patients should be educated on the most recent recommendations on the use of DMTs in the context of pregnancy to avoid deleterious therapeutic inertia.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Jason RosadoAbebe FolaSandrine CojeanVéronique SarrasinRomain CoppéeJustine BaillyRizwana ZaffaroulahAzza BouzayeneLiliane CicéronLudivine HouzéRebecca CrudaleLise MussetMarc ThellierBruno PradinesJérôme ClainJeffrey BaileySandrine HouzéAhmed AboubacarPatrice AgnameyAbou-Bacar AhmedDaniel AjzenbergAdela AngoulvantFrédéric ArieyBenjamin AubryFirouze BanisadrSorya BelazGhania BelkadiGhania Belkacem BelkadiAnne Pauline BellangerDieudonné BembaFarida BenaoudiaMartine BlochFrancoise BotterelVincent BoudenMarie-Elisabeth BougnouxCaren BrumpSophie BrunJulie BrunetBernadette BuretPauline Caraux-PazNourrisson CelineSylvain ClauserElody CollinNaima DahaneCéline DamianiEric DannaouiCéline DardMarie-Laure DardeAnne DebourgogneThierry DelacourJean-Marie DelarbreAnne DelavalVeronique DelceyAnne-Sophie DeleplancqueGuillaume DesoubeauxNathalie DesuremainGisele DewulfRémy DurandMarie-Fleur DurieuxEmmanuel DutoitOdile EloyJean-François FaucherLoïc FavennecAlbert FayeOdile FenneteauCécile FickoEmilie FrealleGilles GargalaCéline GarnaudLudovic De GentileNadine GodineauJudith GorlickiYohann Le GovicAlain GravetNadia GuennouniSamia HamaneThomas HanslikAntoine HugueninJean-Pierre HurstFakhri JeddiLeroy JordanLuce LandraudHélène LapillonneSébastien LarréchéRose-Anne LavergneJean Philippe LemoineCécile LeprinceElodie LestevenAngèle LiCaroline LohmannBasmaciyan LouiseMarie-Claire MachouartCéline MalassigneAnthony MarteauDanièle MaubonEdith MazarsBruno MégarbaneAna Mendes-MoreiraSylvain MermondGwénaël Le MoalAlicia MorenoPierre MornandJean-Benjamin MuratRené NabiasJerome NaudinGilles NevezCéline NourrissonMouri OussamaNathalie ParezOlivier PateyPierre PatozGauthier Pean-De-PonfillyJean Yves PeltierPascale PennAlice PerignonEstelle CateauAlexander W. PfaffSorya BelazMarc PihetJean-Etienne PiloIsabelle PoilanePhilippe PoirierDidier PoissonDenis PonsLauren PullDorothée QuinioDidier RaffenotMatthieu RevestGladys RobertOlivier RogeauxGabrielle RoosenMilène SassoFrançoise SchmittBoualem SendidYaye SenghorMuriel SilvaJean-Yves SiriezEmilie SitterléFrédéric SorgeMaurellet Evrard SylvieIlhame TantaouiDominique ToubasAli Cherif TouilCéline TournusHélène Yera
• Organismes : Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Brown University Biologie moléculaire et immunologie parasitaires et fongiques Université Paris-Saclay Centre National de Référence Paludisme [AP-HP Hôpital Bichat-Claude Bernard] Centre National de Référence Paludisme [AP-HP Hôpital Bichat-Claude Bernard] Risques Infectieux Tropicaux et Microorganismes Emergents Institut Hospitalier Universitaire Méditerranée Infection Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Centre Hospitalier Universitaire d'Amiens-Picardie Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Laboratoire de Parasitologie et Mycologie [CHRU Brest] Microorganismes, Hôtes, Environnements [Équipe du laboratoire EBI Poitiers] Laboratoire de Parasitologie et Mycologie Médicales [CHU de Poitiers] SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Centre Hospitalier Universitaire d'Angers SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Laboratoire de Parasitologie et Mycologie [CHRU Brest]
• Publié dans EBioMedicine le 28/10/2020

---

Résumé : Background: Given the altered responses to both artemisinins and lumefantrine in Eastern Africa, monitoring antimalarial drug resistance in all African countries is paramount. Methods: We measured the susceptibility to six antimalarials using ex vivo growth inhibition assays (IC50) for a total of 805 Plasmodium falciparum isolates obtained from travellers returning to France (2016-2023), mainly from West and Central Africa. Isolates were sequenced using molecular inversion probes (MIPs) targeting forty-three genes across the parasite genome, of which nineteen are drug resistance genes. Findings: Ex vivo susceptibility of all assessed antimalarial compounds was consistent with their potent activity. The median IC50 values for the six drugs were 1.1 nM [IQR: 0.8-1.7] for DHA, 16.7 nM [9.9-27.4] for LMF, 29.5 nM [19.1-45.5] for MFQ, 23.4 nM [17.1-39.0] for MDAQ, 26.7 nM [18.0-41.2] for CQ, and 18.5 nM [15.1-24.3] for PPQ. Only four isolates carried a validated pfkelch13 mutation. Multiple mutations in pfcrt and one in pfmdr1 (Asn86Tyr) were significantly associated with altered susceptibility to multiple drugs, and their frequencies decreased over time. Pfcrt and pfmdr1 mutations altered susceptibility to lumefantrine and mefloquine in an additive manner, with the wild-type haplotype (pfcrt K76-pfmdr1 N86) exhibiting the lowest susceptibility. Interpretation: Our study on P. falciparum isolates from West and Central Africa indicates a low frequency of molecular markers associated with artemisinin resistance and a modest but significant decrease (1.6-2.3X) in the frequency of multidrug resistance markers. These genotypic changes likely mark parasite adaptation to sustained drug pressure and call for intensifying the monitoring of antimalarial drug resistance in Africa.

---

Fichiers liés : main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Nicolas BourgonTina LüdeckeJennifer N LeichliterChris BaumannSven BrömmeMarissa VinkAnne-Marie BaconJeremy MccormackThi Mai Huong NguyenAnh Tuan NguyenPierre-Olivier AntoineJean-Luc PonchePhilippe DuringerFabrice DemeterSouliphane BoualaphaneThonglith LuangkhothElise DufourJean-Jacques HublinKlervia JaouenThomas TütkenAlfredo Martínez-GarcíaPatrick Roberts
• Organismes : Max Planck Institute for Geoanthropology = Max-Planck-Institut für Geoanthropologie Max-Planck-Institut für evolutionäre Anthropologie = Max Planck Institute for Evolutionary Anthropology Max Planck Institute for Chemistry Max Planck Institute for Chemistry Max Planck Institute for Chemistry Eberhard Karls Universität Tübingen = University of Tübingen Max Planck Institute for Chemistry Max Planck Institute for Chemistry Biologie, anthropologie, biométrie, épigénétique, lignées : De la diversité des populations à l'individu, de l'identification à l'identité Goethe University Frankfurt = Goethe-Universität Frankfurt am Main Institut des Sciences de l'Evolution de Montpellier Université de Montpellier Laboratoire Image, Ville, Environnement Institut de physique du globe de Strasbourg Ecole et Observatoire des sciences de la terre Københavns Universitet = University of Copenhagen = Université de Copenhague Université Paris Cité Archéozoologie - Archéobotanique. Sociétés, pratiques et environnements Collège de France - Chaire Paléoanthropologie Max-Planck-Institut für evolutionäre Anthropologie = Max Planck Institute for Evolutionary Anthropology Géosciences Environnement Toulouse Max-Planck-Institut für evolutionäre Anthropologie = Max Planck Institute for Evolutionary Anthropology Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University Max Planck Institute for Chemistry Max Planck Institute of Geoanthropology
• Publié dans Science Advances le 21/10/2020

---

Résumé : Southeast Asia boasts some of the world's most diverse ecosystems, yet it has experienced a dramatic decline in biodiversity due to extensive deforestation in recent decades. Understanding how species adapted to past habitat loss could provide valuable insights for developing effective conservation strategies to address current threats. We apply state-of-the-art isotope measurements of enamel-bound zinc (δ⁶⁶Zn) and nitrogen (δ¹⁵N enamel ) analyses to fossil mammal teeth from Coc Muoi [148 to 117 thousand years (ka) and Duoi U'Oi (70 to 60 ka)], Vietnam. Alongside published regional data (δ⁶⁶Zn, δ¹³C, and δ¹⁸O), we explore how different taxa adapt their diets and behaviors in the face of climatic and environmental changes. We show that foraging in diverse habitats and diversifying food consumed is associated with extant species, while extinct or locally extirpated taxa show these traits to a lesser extent. We underscore the precariousness of certain species and the pressing need for robust conservation policies to safeguard Southeast Asia's biodiversity.

---

Fichiers liés : Bourgon2025SciAdv.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Florian ChateletSylvie ChevretNicolas FakhryCaroline EvenOlivier MalardErwan de MonèsNicolas SaroulFrançois MouawadMarie de BoutrayOlivier MauvaisSébastien VergezDiane EvrardChristian Adrien RighiniPhilippe SchultzRobin BaudouinGilles PoissonnetSarah. AtallahFabienne HarounSylvain MorinièreCamille EvrardPierre PhilouzeA. PaascheMaria LesnikYann LelongePhilippe HermanBenjamin VerillaudC. Ala-EddineK. AubryE. BabinC. BachC. BadoualA.C. BaglinB. BarryV. BastitBertrand BaujatK. BenezeryR.J. BensadounN. BenzerdjebM. BernadachC. BertolusJérémie BettoniA. Biet-HornsteinD. BodmerP. BoisselierC. Boulagnon-RombiL. BozecA. Bozorg GrayeliE. BrenetL. BrugelG. CalaisV. CalugaruS. CambyO. CasiraghiE. CassagnauC. CastainJ. CastelliP. CeruseF. ChabolleD. ChevalierO. ChoussyM. ClasseF. ClatotEmilien ColinJean-Marc ConstansA. CosteF. CosteV. CostesJ.P. CottierAlexandre CoutteJ.P. CristofariD. CupissolJ. DelgrandeJean-Pierre DelordBernard DevauchelleL. DigueGilles DolivetM. DoréS. DufloXavier DufourC. DupinE. EkerF. EspitalierC. EvenCamille ÉvrardE. FabianoS. FaivreN. FakhryF.R. FerrandJ. FrandonD. FranettiL. de GaboryC. GalyM. GarcierR. GarrelH. GauthierL. GilainS. GuihardS. GuillermC. HalimiS. HansP. HermanAline HouessinonM. HourseauF. HuguetE. JadaudRoger JankowskiC. JeanneF. JegouxM. JuliéronR. KaciM.-C. KaminskyH. de KermadecF. KolbS. KrepsM. LaadhariJ. Lacau Saint GuilyL. LaccoureyeM. LaeF. LagardeA. LagrangeB. LallemantM. LamuragliaP. LangM. LapeyreA. LapierreA. Lasne CardonC. Le TourneauG. LefebvreM. LefevreY. LelongeX. LeroyM. LesnikX. LiemC. LinassierPhilippe MaingonC. MajoufreO. MalardG. MaloufC. MarchandJ.-P. MarieT. MaurinaO. MauvaisJ.-C. MerolJ. MichelG. MineurS. MirafzalH. MirghaniA. ModestoS. Molinier-BlossierE. de MonèsS. MorinièreF. MouawadA. Moya-PlanaL. MullerE. MusatF. NguyenGeorges NoelF.R. Obongo-AngaM. OneaH. OrliacC. PageV. PatronJ. PestreN. Pham DangP. PhilouzeG. PoissonnetC. PonsC. PouliquenJ.-M. PradesA. PrevostC. QueirosA. RahmaniA. RambeauL. RaminS. RenardC.A. RighiniF. RollandE. SaadaF. SacinoS. SalasN. SaroulP. SchultzA. SimonaggioO. SterkersV. StrunskiA. SudakaS. Xu-ShanR. TaouachiM. TassartSylvie TestelinJ. ThariatM. Timar DavidA. TimochenkoB. ToussaintE. Uro CosteG. ValetteT. van den AbbeeleA. VaroquauxE. VauleonS. VergezB. VerillaudJ. VillaA. VillepeletM. VolondatN. VulquinI. WagnerMichel WassefL. WebertS. Wong
• Organismes : Université Paris Cité Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation | Epidémiologie Clinique, STatistique, pour la Recherche en Santé AP-HP - Hôpital Saint-Louis [Paris] Laboratoire Parole et Langage Hôpital de la Conception [CHU - APHM] Département Anesthésie, Chirurgie et Interventionnel [Gustave Roussy] Regenerative Medicine and Skeleton Bioingénierie tissulaire CHU Clermont-Ferrand Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 Robotique médicale et mécanismes parallèles Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire de Besançon Centre Hospitalier Universitaire de Toulouse AP-HP - Hôpital Bichat - Claude Bernard [Paris] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Universitaire [Strasbourg] Biomatériaux et Bioingénierie UFR Sciences de la santé Simone Veil AP-HP - Hôpital Necker - Enfants Malades Institut Universitaire de la Face et du Cou [Nice] AP-HP - Hôpital de la Pitié Salpêtrière Université Paris Cité Centre Hospitalier Régional Universitaire de Tours Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Hospices Civils de Lyon Chirurgie maxillofaciale et Stomatologie [CHU Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Chirurgie maxillofaciale et Stomatologie [CHU Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Centre Hospitalier Universitaire d'Amiens-Picardie CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Centre Hospitalier Universitaire d'Amiens-Picardie CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Chirurgie maxillofaciale et Stomatologie [CHU Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Chirurgie maxillofaciale et Stomatologie [CHU Amiens] CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516
• Publié dans EJSO - European Journal of Surgical Oncology le 22/10/2020

---

Résumé : Objectives: The management of the facial nerve (FN) is a major issue in parotid cancer, especially when there is no preoperative facial palsy and FN invasion is discovered intraoperatively. The aim of this study was to assess the impact of FN resection in patients with parotid cancer abutting the FN, without pretreatment facial palsy, using a propensity score matching. Materials and methods: Data from all patients treated between 2009 and 2020 for a primary parotid cancer abutting or invading the FN but without pretreatment facial palsy were extracted from the national multicentric REFCOR database. Three different definitions of tumors abutting the FN were used for sensitivity analyses, in a retrospective setting. Propensity score matching was used to assess the impact of FN resection on disease-free survival (DFS), overall survival (OS) and locoregional recurrence-free survival (LRRFS). Results: A total of 163 patients with parotid cancer abutting or invading the FN without pretreatment facial palsy were included. Among them, 99 patients (61 %) underwent FN resection. After overlap weighting and multiple imputation, no benefit of FN resection over preservation was found in terms of OS (HR = 1.21, p = 0.6), DFS (HR = 0.88, p = 0.5) and LRRFS (HR = 0.99, p = 1). Sensitivity analyses revealed similar results, and no significant efficacy was found in the subgroup analyses. Conclusion: In this retrospective study with propensity score analysis, FN resection did not improve survival outcomes in patients without preoperative facial palsy treated surgically for a primary parotid cancer abutting the FN. In line with recent guidelines, the results of this study suggest that FN preservation should be considered whenever possible in this specific group of patients.

---

Fichiers liés : PIIS0748798324008035-2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Kaori SaitohMohamed LajnefWahid BoukouaciMyrtille AndreChristelle AndrieuBruno AouizerateCaroline BarauJihène BouassidaDelphine CapdevielleIsabelle ChereauJulie Clauss-KobayashiNathalie CoulonJean-Michel DoreyCaroline DubertretEric FakraGuillaume FondTudi GozéP. Le CorvoisierSylvain LeignierPierre-Michel LlorcaJasmina MalletDavid MisdrahiNicolas OriolBaptiste PignonRomain ReyPaul RouxFranck SchürhoffBenoît SchorrMathieu UrbachEtienne VeryChing-Lien WuMarion LeboyerOphélia GodinRyad Tamouza
• Organismes : IMRB - "Neuropsychiatrie translationnelle" [Créteil] Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] Fondation FondaMental [Créteil] IMRB - "Neuropsychiatrie translationnelle" [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] IMRB - "Neuropsychiatrie translationnelle" [Créteil] Pôle de Psychiatrie [CHU Henri Mondor] Fondation FondaMental [Créteil] Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondation FondaMental [Créteil] Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] Centre hospitalier Charles Perrens [Bordeaux] Nutrition et Neurobiologie intégrée Fondation FondaMental [Créteil] Plateforme de Ressources Biologiques [Henri Mondor AP-HP, Créteil] Fondation FondaMental [Créteil] IMRB - "Neuropsychiatrie translationnelle" [Créteil] Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [Montpellier] Institut de Génomique Fonctionnelle Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Institut Pascal Fondation FondaMental [Créteil] Centre Hospitalier Universitaire [Strasbourg] Sociétés, acteurs, gouvernement en Europe Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] AP-HP - Hôpital Louis Mourier Institut de psychiatrie et neurosciences de Paris Fondation FondaMental [Créteil] Université Sorbonne Paris Cité Équipe Troubles psychiatriques, Recherche en Neurosciences et Recherche Clinique - Psychiatric Disorders, Neuroscience Research and Clinical Research Team Université Jean Monnet - Saint-Étienne Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre d'études et de recherche sur les services de santé et la qualité de vie Equipe de Recherche sur les Rationalités Philosophiques et les Savoirs Service Psychiatrie, Psychothérapies et Art-thérapie [CHU Toulouse] Fondation FondaMental [Créteil] Institut National de la Santé et de la Recherche Médicale Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Institut Pascal CHU Clermont-Ferrand Fondation FondaMental [Créteil] Association française de psychiatrie biologique et neuropsychopharmacologie = French Society for Biological Psychiatry and Neuropsychopharmacology Fondation FondaMental [Créteil] Institut de psychiatrie et neurosciences de Paris AP-HP - Hôpital Louis Mourier Université de Bordeaux Centre National de la Recherche Scientifique Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre de recherche en épidémiologie et santé des populations Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre de recherche en épidémiologie et santé des populations Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Fondation FondaMental [Créteil]
• Publié dans Psychiatry Research le 25/10/2020

---

Résumé : Schizophrenia (SZ) is characterized by a variable clinical expression and course peppered/hampered by severe complications. In particular, resistance to treatment (overall-TRS, treatment resistant SZ including UTRS, ultra-TRS) and metabolic syndrome (MetS) are highly prevalent, and both demonstrated to be underpinned, at least partly, by pro-inflammatory processes. Given that such processes also underlie SZ per se , we hypothesized that potential inter-twinning between SZ-and MetS-related inflammatory processes may exert a combined effect on the risk of having overall-TRS/UTRS. A total of 419 outpatients with SZ underwent clinical assessments and blood sample collection. Using the values of circulating levels of eleven cytokines, we built a ratio between pro-and anti-inflammatory components respectively corresponding to the immunoinflammatory response system (IRS) and the compensatory immunoregulatory reflex system (CIRS) which overall reflect the underlying in-flammatory status. Such ratios allowed to categorize the patients according to Inflammation and MetS on four categories as follow: symbolscript symbolscript symbolscript and Inflam-mation(-)MetS(-). Multivariate logistic regression analysis showed that the combination of inflammation and MetS modulate the risk of having the overall-TRS symbolscript symbolscript 95 %CI [1.04-5.00], p symbolscript 0.039 and symbolscript symbolscript 95 % CI [1.76-11.97], p symbolscript 0.002 overall in comparison to Inflammation(-)MetS(-)]. Moreover, we observed that individuals with UTRS are those associated with both inflammation and/or MetS. Our results demonstrated the potential combined effect of MetS and inflammation towards resistance to treatment. Given that overall-TRS/UTRS are unpredictable while both inflammation and MetS can be early detected and managed, our findings shed new light on the possibility to better prevent treatment resistance in SZ.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Etienne BrainOlivier MirEmmanuelle BourboulouxOlivier RigalJean-Marc FerreroSylvie KirscherDjelila AllouacheVéronique d'HondtAude-Marie SavoyeXavier DurandoFrançois DuhouxLaurence Venat-BouvetEmmanuel BlotEmmanuel BlotJean-Luc CanonFlorence Rollot-TradHervé BonnefoiTelma RoqueJérôme LemonnierAurélien LatoucheJulie HenriquesMagali Lacroix-TrikiDewi VernereyVéronique D’hondtSophie Abadie-LacourtoisiePaul CottuGilles RomieuEmmanuelle MalaurieSylvain LadoireCatherine TerretVéronique ServentLoic MoureyClaudia LefeuvreElisabeth CarolaLionel UwerVéronique GirrePierre GuilletMarc DebledLucie Monceau-BarouxJean-Claude DarmonFrancesco del PianoLaetitia JolyHugues BourgeoisValérie DelecroixFrédérique RousseauJean-Philippe JacquinThierry PetitLaetitia StefaniClaire FalandryOana CojocarasuAnne Mercier-BlasCarol AlliotHeba DawoodEric RaymondBénédicte PetitChristophe TournigandDenis HeitzJean-François BerdahMarc BaronPeter VuylstekeMarie-Pascale GraasPhilippe HouyauPhilippe GlorieuxAnnelore BarbeauxVictor SimmetJérôme DaubaFrederic ForgetJean-Emmanuel KurtzLionel DuckGuillermo Reyes OrtegaSophie BarthierLionel d'HondtEtienne SucChantal Bernard-MartyLaurent CanyNadia RabanGaëtan Des GuetzJorge AyllonVincent Richard
• Organismes : Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand]
• Publié dans The Lancet le 02/11/2020

---

Résumé : For women aged 70 years or older with oestrogen receptor-positive HER2-negative invasive breast cancer, hormonotherapy is a standard adjuvant treatment, while the role of chemotherapy is debated. We aimed to assess the effect of adjuvant chemotherapy on overall survival in these older patients with high-risk tumours according to a prognostic genomic signature.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Olivier PaccoudOlivier LortholarySebastien ImbertValérie BruKarine Boukris-SitbonThomas ObadiaFrederic DalleLilia HasseineFlorent MorioAntoine HugueninPhilippe PoirierLoïc FavennecJulie BonhommeAlexandre AlanioFanny LanternierM. Desnos-OllivierTaieb ChouakiMarc PihetAnne-Pauline BellangerMagalie DemarNicole Desbois-NogardMuriel NicolasMarie-Fleur DurieuxMilène SassoEstelle CateauJean-Pierre GangneuxCaroline MahincSophie CassaingAdélaïde ChesnayGuillaume DesoubeauxAndré PaugamElisabeth ChachatyMarie-Elisabteth BougnouxLilia MerabetPatricia MarianiMaité Micaelo
• Organismes : AP-HP - Hôpital Necker - Enfants Malades Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Mycologie translationnelle - Translational Mycology AP-HP - Hôpital Necker - Enfants Malades Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Mycologie translationnelle - Translational Mycology CHU de Bordeaux Pellegrin [Bordeaux] Centre Hospitalier Universitaire [Strasbourg] Pathogens Host Arthropod Vectors Interfaces Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Mycologie translationnelle - Translational Mycology Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Hôpital l'Archet [Nice] Cibles et Médicaments des Infections et de l'Immunité - UR 1155 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle Hôpital universitaire Robert Debré [Reims] Infection Inflammation et Interaction Hôtes Pathogènes [CHU Clermont-Ferrand] Université Clermont Auvergne CHU Clermont-Ferrand CHU Rouen Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Mycologie translationnelle - Translational Mycology AP-HP - Hôpital Saint-Louis [Paris] Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Mycologie translationnelle - Translational Mycology AP-HP - Hôpital Necker - Enfants Malades Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Mycologie translationnelle - Translational Mycology SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques Infections Respiratoires Fongiques Centre Hospitalier Universitaire d'Angers
• Publié dans The Lancet Regional Health - Europe le 21/04/2021

---

Résumé : Background Intravenous injection drug use (IVDU) is an established but infrequent risk factor for yeast fungaemia. We aimed to identify features and outcomes of yeast fungaemia associated with IVDU in a nationwide surveillance network in France. Methods We prospectively included episodes of yeast fungaemia in adults between 2012 and 2022. Episodes with any history of IVDU were considered IVDU-associated. We compared clinical characteristics, infecting species, antifungal treatments, and 90-day mortality between groups. We used Fisher's exact test for categorical variables and the Kruskal–Wallis test for continuous variables. Findings We recorded 9549 episodes of yeast fungaemia among 9132 adults. Among these, 183 (1·9%) were IVDU-associated. Compared with non-IVDU, individuals with IVDU-associated fungaemia were younger and less likely to have a history of malignancy (13·8%, 20/145 vs. 49·5%, 4447/8987, p < 0·0001) or recent surgery (24·3%, 34/140 vs. 37·3%, 3261/8,733, p = 0·0014), and more likely to have deep-seated infections (14·5%, 21/145 vs. 3·4%, 307/8987, p < 0·0001). IVDU cases less often involved Candida albicans (30·1%, 55/183 vs. 47·6%, 4458/9366, p < 0·0001) and more often involved mixed-species infections (13·1%, 24/183 vs. 4·3%, 402/9366), p < 0·0001. Meyerozyma guilliermondii and Wickerhamomyces anomalus were overrepresented among IVDU cases (6·0%, 11/183 vs. 0·5%, 48/9366, p < 0·0001 and 5·5%, 10/183 vs. 0·05%, 5/9366, p < 0·0001, respectively). The crude 90-day case-fatality ratio was 20·7% (95% CI: 13·7%–29·2%) in the IVDU group versus 48·4% (95% CI: 47·3–49·5%) for non-IVDU. Interpretation IVDU-associated yeast fungaemia presents distinct clinical and microbiological characteristics, highlighting the need for tailored diagnosis and management.

---

Fichiers liés : PIIS2666776225001577.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2025
• Auteurs : Camille RobinFabien RollotMathilde LefortRomain CaseySandra VukusicGuillaume MatheyJonathan CironJérôme de SèzeBruno StankoffÉlisabeth MaillartAurélie RuetPierre M. LabaugeArnaud KwiatkowskiHélène ZéphirCaroline PapeixGilles-Louis DeferChristine Lebrun-FrenayThibault MoreauDavid-Axel LaplaudEric BergerPierre ClavelouEric ThouvenotOlivier HeinzlefJean PelletierOlivier CasezBertrand BourreAbir WahabLaurent MagySolène MoulinJean-Philippe CamdessanchéInès DoghriMariana SarovKarolina HankiewiczCorinne PottierAmélie dos SantosÉric ManchonMaya TchikviladzeChantal NifleAnne KerbratGilles EdanEmmanuelle Le PageLaure Michel
• Organismes : Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Observatoire Français de la Sclérose En Plaques [Lyon] Fondation Eugène Devic EDMUS Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Observatoire Français de la Sclérose En Plaques [Lyon] Fondation Eugène Devic EDMUS Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Observatoire Français de la Sclérose En Plaques [Lyon] Fondation Eugène Devic EDMUS INterdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes Service de neurologie [CHRU Nancy] Institut Toulousain des Maladies Infectieuses et Inflammatoires Centre Ressources et Compétences sclérose en plaques (CRC-SEP) [CHU Toulouse] Centre Hospitalier Universitaire [Strasbourg] CIC Strasbourg Institut du Cerveau = Paris Brain Institute Centre de Ressources et de Compétences Sclérose en Plaques (CRC-SEP) Paris AP-HP - Hôpital de la Pitié Salpêtrière Centre de Ressources et de Compétences Sclérose en Plaques (CRC-SEP) Paris Centre Hospitalier Universitaire de Bordeaux Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier Université catholique de Lille - Faculté de théologie Groupement des Hôpitaux de l'Institut Catholique de Lille Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Université Paris Cité CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Nice UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique Centre Hospitalier Régional Universitaire de Besançon CHU Louise Michel [Clermont-Ferrand] Neuro-Dol Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Clermont-Ferrand] Service de Neurologie [CHU Nimes] Institut de Génomique Fonctionnelle Centre Hospitalier Intercommunal de Poissy/Saint-Germain-en-Laye Centre de Ressources et de Compétences Sclérose en Plaques (CRC-SEP) Paris Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM] Pôle Psychiatrie et Neurologie [Grenoble] Université Grenoble Alpes CHU Rouen AP-HP - Hôpital Henri-Mondor CHU Limoges Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Régional Universitaire de Tours Service de neurologie [Le Kremlin Bicêtre] Centre Hospitalier Universitaire de La Réunion Hôpital NOVO Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Centre Hospitalier de Gonesse Hôpital Foch [Suresnes] Centre Hospitalier de Versailles André Mignot Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Microenvironment and B-cells: Immunopathology, Cell Differentiation, and Cancer Centre d'Investigation Clinique [Rennes]
• Publié dans Neurology le 01/11/2020

---

Résumé : Background and objectives: The therapeutic strategy in patients with late-onset MS (LOMS) remains poorly defined. In this study, we aimed to evaluate both clinical and MRI outcomes between 2 cohorts of patients with relapsing-remitting LOMS treated or not yet treated. Methods: Patients with relapsing-remitting MS were included for the analysis if disease onset occurred after 55 years and if they had at least one follow-up visit. The primary outcome was time to first relapse between 2 matched groups of patients with LOMS (treated and not yet treated). Secondary outcomes were as follows: (1) time to first confirmed disability progression (CDP), (2) time to first progression independent of relapse activity (PIRA) event, (3) time to secondary progression (SPMS), (4) time to first MRI activity, and (5) serious infection incidence rates (IIRs). For the comparative analyses, we adopted a time-dependent propensity score matching approach. Results: A total of 881 patients fulfilled the inclusion criteria. The mean (SD) age at onset was 59.9 (4.43) years. After applying propensity score matching, 436 patients were matched. The mean (SD) follow-up duration was 5.2 (4.27) years in the treated group and 5.0 (3.86) years in the not-yet-treated group. Mean (SD) time to first relapse was significantly longer in the treated group compared with the not-yet-treated group (7.0 years [0.33] vs 5.4 years [0.33]; p = 0.001). Mean (SD) time to first MRI activity was significantly longer in the treated group (5.9 years [0.33] vs 5.0 years [0.33]; p = 0.049). However, the mean time to CDP, PIRA, or SPMS was not different between the 2 groups (difference = 0.32 years; p = 0.585 for CDP; difference = 0.40 years; p = 0.442 for PIRA; difference = -0.02 years; p = 0.952 for SPMS). No increase in serious IIRs was observed with an incidence rate ratio of 0.38 (95% CI 0.07-2.10, p = 0.265) in the never-treated group compared with the treated one. Discussion: This study demonstrates a beneficial effect of disease-modifying therapy (DMT) on disease activity in patients with LOMS but without significant impact on disability progression. Main limitations are linked to the challenge of data collection and to the baseline imbalances between the 2 groups. Classification of evidence: This study provides Class III evidence that in patients with LOMS, treatment with DMTs is associated with a longer time to first relapse compared with those not treated with DMTs.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/07/2025
• Auteurs : Pauline JaubertCamille LoretTanya StojkovicShahram AttarianNathalie Bonello‐palotFrançoise BouhourJean-Philippe CamdessanchéJulien CassereauJean-Baptiste ChansonPascal CintasAlain CréangeFlorence EsselinSteeve GenestetSophie GiordanoCyril GitiauxMarine Guillaud‐batailleArnaud IsapofDeiva KumaranCéline LabeyrieVincent LaugelSarah Leonard‐louisPierre LozeronLaurent MagySandra MercierPhilippe MerleMaud MichaudGuillaume NicolasElisabeth OllagnonYann PereonAngela PumaVianney PoinsignonSusana Quijano RoyGuilhem SoleCéline TardLéo VidoniAnne‐sophie LiaAndoni Echaniz-Laguna
• Organismes : Marseille medical genetics - Centre de génétique médicale de Marseille Filière Neuromusculaire Marseille medical genetics - Centre de génétique médicale de Marseille Centre Hospitalier Universitaire d'Amiens-Picardie
• Publié dans European Journal of Neurology le 22/10/2020

---

Résumé :

---

Fichiers liés : Euro J of Neurology - 2025 - Jaubert - Nationwide Phenotypic and Genotypic Characterisation of 103 Patients With SH3TC2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/07/2025
• Auteurs : Jean-Philippe MatasJ. John Soundar JeromePierre Trontin
• Organismes : Laboratoire de Mecanique des Fluides et d'Acoustique Université Claude Bernard Lyon 1 Université Claude Bernard Lyon 1 Laboratoire de Mecanique des Fluides et d'Acoustique Université Claude Bernard Lyon 1 Laboratoire de Mecanique des Fluides et d'Acoustique
• Publié dans Physics of Fluids le 02/11/2020

---

Résumé : We investigate the emergence of patterns as liquid is entrained along the exterior surface of a partially immersed cylinder rotating around its horizontal axis. Our findings reveal that the coating flow exhibits marked axial variations, leading to the formation of a series of nearly vertical, slender liquid structures whose shape and location fluctuate over time. Measurements indicate that the spacing between these liquid ribs depends only weakly upon velocity, viscosity, or confinement conditions around the cylinder. Additionally, Direct Numerical Simulations (DNS) successfully captured the experimentally observed behavior and the values of the associated wavelength. We discuss suspected mechanisms for the instability: a Saffman-Taylor instability, where the pressure gradient building within the extracted liquid film drives the instability ; or a Rayleigh-Taylor instability driven by gravity. Both mechanisms predict the right order of magnitude for the spacing of the ribs, controlled by the capillary length.

---

Fichiers liés : 2025 POF25-AR-SSH2024-07658.pdf

---

Source